A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF TWO STEADY-STATE DOSE LEVELS OF PF-07081532 ON THE PHARMACOKINETICS OF SINGLE-DOSE MIDAZOLAM, OMEPRAZOLE AND AN ORAL CONTRACEPTIVE, AND THE EFFECT OF STEADY-STATE SEMAGLUTIDE ON THE PHARMACOKINETICS OF SINGLE-DOSE MIDAZOLAM, IN OBESE ADULT FEMALE PARTICIPANTS
Latest Information Update: 18 Dec 2024
At a glance
- Drugs Lotiglipron (Primary) ; Semaglutide (Primary) ; Ethinylestradiol; Levonorgestrel; Midazolam; Omeprazole
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 19 Dec 2023 Status changed from completed to discontinued based on based on pharmacokinetic datafrom Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.
- 08 Nov 2023 Status changed from discontinued to completed.
- 26 Jun 2023 According to a Pfizer media release, based on pharmacokinetic data from NCT05671653, NCT05788328 and laboratory measurements of elevated transaminases in NCT05579977, the company has decided to terminate the clinical development of lotiglipron.